Kestrel Fund adds 426K PROCEPT BioRobotics shares

PROCEPT BioRobotics Corp director-linked entity Kestrel Fund, L.P. reported open-market purchases of 426,262 shares of common stock over several days.

Rhea-AI Filing Summary

PROCEPT BioRobotics Corp director-linked entity Kestrel Fund, L.P. reported open-market purchases of 426,262 shares of common stock over several days. The buys occurred on March 5, 6 and 9, 2026 at weighted average prices generally between the low $20s and mid $20s per share, as detailed in price ranges in the footnotes. The filing also shows 35,152 shares held directly and 14,363 shares held indirectly by The 2:22 DNA Trust as of March 5, 2026. Antal Rohit Desai, a director and managing partner of CPMG, Inc., may be deemed to share voting and investment power over Kestrel Fund holdings but disclaims beneficial ownership except to the extent of any pecuniary interest.

Insider Trade Summary

Net Buyer: 426,262 shares

Net Buy 9 txns

Insider Desai Antal Rohit

Role Director

Bought 426,262 shs ($10.48M)

Type	Security	Shares	Price	Value
Purchase	Common Stock	43,581	$24.0816	$1.05M
Purchase	Common Stock	53,818	$24.9052	$1.34M
Purchase	Common Stock	1,300	$25.4173	$33K
Purchase	Common Stock	106,554	$23.3282	$2.49M
Purchase	Common Stock	53,763	$24.1019	$1.30M
Purchase	Common Stock	142,498	$25.4391	$3.63M
Purchase	Common Stock	24,748	$26.4073	$654K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 426,262 shares (Indirect, Kestrel Fund, L.P.); Common Stock — 35,152 shares (Direct); Common Stock — 14,363 shares (Indirect, By The 2:22 DNA Trust)

Footnotes (8)

1. F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.0645 to $26.0213, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
2. F2. CPMG, Inc. is the general partner and investment manager of Kestrel Fund, L.P. Antal Desai, a member of the Issuer's board of directors and a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by Kestrel Fund, L.P. Mr. Desai disclaims beneficial ownership of the shares beneficially owned by Kestrel Fund, L.P. except to the extent of any pecuniary interest therein.
3. F3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.10 to $26.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
4. F4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.785 to $23.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
5. F5. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.79 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
6. F6. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.40 to $24.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
7. F7. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.40 to $25.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
8. F8. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.40 to $25.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did PROCEPT BioRobotics (PRCT) report on this Form 4?

The Form 4 reports that Kestrel Fund, L.P., an entity associated with director Antal Rohit Desai, purchased a total of 426,262 shares of PROCEPT BioRobotics common stock in open-market transactions across March 5, 6 and 9, 2026, increasing its reported indirect holdings.

On what dates did Kestrel Fund, L.P. buy PROCEPT BioRobotics (PRCT) shares?

Kestrel Fund, L.P. reported open-market purchases of PROCEPT BioRobotics common stock on March 5, 6 and 9, 2026. Each day included multiple transactions, with individual trade prices summarized as weighted average prices and detailed price ranges provided in the Form 4 footnotes.

How many PROCEPT BioRobotics (PRCT) shares does Kestrel Fund, L.P. hold after these transactions?

After the reported open-market purchases, one line in the Form 4 shows Kestrel Fund, L.P. holding 426,262 shares of PROCEPT BioRobotics common stock indirectly. Other lines show earlier intermediate totals as purchases accumulated across the March 5–9, 2026 trading period.

What prices did Kestrel Fund, L.P. pay for PROCEPT BioRobotics (PRCT) shares?

The reported weighted average purchase prices range around the low to mid $20s per share, including figures like $23.3282, $24.1019, and $25.4391. Footnotes state these averages reflect multiple trades within specified price ranges on each transaction date.

How are Antal Rohit Desai and Kestrel Fund, L.P. related in this PROCEPT BioRobotics (PRCT) filing?

The Form 4 explains that CPMG, Inc. is the general partner and investment manager of Kestrel Fund, L.P., and director Antal Rohit Desai is a shareholder and managing partner of CPMG, Inc. He may share voting and investment power but disclaims beneficial ownership except for pecuniary interest.

What additional PROCEPT BioRobotics (PRCT) holdings are reported besides Kestrel Fund, L.P.?

The filing lists 35,152 shares of PROCEPT BioRobotics common stock held directly, and 14,363 shares held indirectly by The 2:22 DNA Trust as of March 5, 2026. These entries are reported as holdings, not new open-market purchase transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/09/2026 - 07:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Desai Antal Rohit

(Last) (First) (Middle)

C/O PROCEPT BIOROBOTICS CORPORATION

150 BAYTECH DRIVE

(Street)

SAN JOSE CA 95134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PROCEPT BioRobotics Corp [ PRCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		P		142,498	A	$25.4391(1)	142,498	I	Kestrel Fund, L.P.(2)
Common Stock	03/05/2026		P		24,748	A	$26.4073(3)	167,246	I	Kestrel Fund, L.P.(2)
Common Stock	03/06/2026		P		106,554	A	$23.3282(4)	273,800	I	Kestrel Fund, L.P.(2)
Common Stock	03/06/2026		P		53,763	A	$24.1019(5)	327,563	I	Kestrel Fund, L.P.(2)
Common Stock	03/09/2026		P		43,581	A	$24.0816(6)	371,144	I	Kestrel Fund, L.P.(2)
Common Stock	03/09/2026		P		53,818	A	$24.9052(7)	424,962	I	Kestrel Fund, L.P.(2)
Common Stock	03/09/2026		P		1,300	A	$25.4173(8)	426,262	I	Kestrel Fund, L.P.(2)
Common Stock								35,152	D
Common Stock								14,363	I	By The 2:22 DNA Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.0645 to $26.0213, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

2. CPMG, Inc. is the general partner and investment manager of Kestrel Fund, L.P. Antal Desai, a member of the Issuer's board of directors and a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by Kestrel Fund, L.P. Mr. Desai disclaims beneficial ownership of the shares beneficially owned by Kestrel Fund, L.P. except to the extent of any pecuniary interest therein.

3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.10 to $26.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.785 to $23.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.79 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.40 to $24.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

7. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.40 to $25.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

8. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.40 to $25.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

	/s/ Antal Rohit Desai	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.